Association Between Use of Sodium-Glucose Cotransporter-2 Inhibitors or Angiotensin Receptor-Neprilysin Inhibitor and the Risk of Atherosclerotic Cardiovascular Disease With Coexisting Diabetes and Heart Failure.
Ya-Wen LinChun-Hsiang LinCheng-Li LinChe-Huei LinMing-Hung LinPublished in: Journal of cardiovascular pharmacology and therapeutics (2024)
The study suggests that the use of SGLT2 inhibitors, alone or in combination with Entresto, may be effective in reducing the risk of ASCVD and its associated adverse outcomes in patients with diabetes and heart failure. This finding has important implications for the management of these conditions.
Keyphrases
- heart failure
- cardiovascular disease
- type diabetes
- left ventricular
- cardiac resynchronization therapy
- acute heart failure
- atrial fibrillation
- angiotensin ii
- glycemic control
- cardiovascular risk factors
- metabolic syndrome
- angiotensin converting enzyme
- adipose tissue
- cardiovascular events
- skeletal muscle
- binding protein